RESEARCH ARTICLE

REVISED Initial study of three different pathogenic microorganisms by gas chromatography-mass spectrometry [version 3; peer review: 3 approved]

Najmeh Karami¹, Fateme Mirzajani², Hassan Rezadoost³, Abdollah Karimi¹, Fatemeh Fallah¹, Alireza Ghassempour³, Atusa Aliahmadi⁴

¹Pediatric Infections Research Center, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Biotechnology, Faculty of Renewable Energies & New Technologies Engineering (NTE), Shahid Beheshti University, Tehran, Iran

³Department of Phytochemistry, Medicinal plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran

⁴Department of Biology, Medicinal plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran

V3 First published: 10 Aug 2017, 6:1415
<https://doi.org/10.12688/f1000research.12003.1>

Second version: 11 Dec 2017, 6:1415
<https://doi.org/10.12688/f1000research.12003.2>

Latest published: 18 Jan 2018, 6:1415
<https://doi.org/10.12688/f1000research.12003.3>

Abstract

Background: Diagnoses of respiratory tract infections usually happen in the late phase of the disease and usually result in reduction of the pathogen load after broad-spectrum antibiotic therapy, but not in eradication of the pathogen. The development of a non-invasive, fast, and accurate method to detect pathogens has always been of interest to researchers and clinicians alike. Previous studies have shown that bacteria produce organic gases. The current study aimed to identify the volatile organic compounds (VOCs) produced by three respiratory tract pathogens, including *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans*.

Methods: The VOCs produced were identified by gas chromatography-mass spectrometry (GC-MS), with prior collection of microbial volatile compounds using solid phase microextraction (SPME) fiber. The volatile compounds were collected by obtaining bacterial headspace samples.

Results: Results showed that these three organisms have various VOCs, which were analyzed under different conditions. By ignoring common VOCs, some species-specific VOCs could be detected. The most important VOC of *E. coli* was indole, also some important VOCs produced by *S. aureus* were 2,3-pentandione, cis-dihydro- α -terpinyl acetate, 1-decyne, 1,3-heptadiene, 2,5-dimethyl pyrazine, ethyl butanoate and cyclohexene, 4-ethenyl. Furthermore, most of the identified compounds by *C. albicans* are alcohols.

Open Peer Review

Approval Status

	1	2	3
version 3 (revision) 18 Jan 2018			
version 2 (revision) 11 Dec 2017	 view		 view
version 1 10 Aug 2017	 view	 view	 view

1. **Paul Brinkman** , Academic Medical Center, Amsterdam, The Netherlands

2. **Amy Scott-Thomas**, University of Otago, University of Otago, New Zealand

3. **Norman Ratcliffe**, University of the West of England, Bristol, UK

Any reports and responses or comments on the article can be found at the end of the article.

Conclusions: The detection of VOCs produced by infectious agents maybe the key to make a rapid and precise diagnosis of infection, but more comprehensive studies must be conducted in this regard.

Keywords

Candida albicans, Escherichia coli, gas chromatography-mass spectrometry, Staphylococcus aureus, volatile organic compounds

Corresponding author: Atusa Aliahmadi (atousa.aliahmadi@gmail.com)

Author roles: Karami N: Investigation, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; Mirzajani F: Formal Analysis, Software, Validation; Rezadoost H: Methodology, Software; Karimi A: Methodology, Resources; Fallah F: Methodology, Visualization; Ghassempour A: Methodology, Visualization; Aliahmadi A: Conceptualization, Supervision

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Shahid Beheshti University of Medical Sciences
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Karami N *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Karami N, Mirzajani F, Rezadoost H *et al.* **Initial study of three different pathogenic microorganisms by gas chromatography-mass spectrometry [version 3; peer review: 3 approved]** F1000Research 2018, 6:1415
<https://doi.org/10.12688/f1000research.12003.3>

First published: 10 Aug 2017, 6:1415 <https://doi.org/10.12688/f1000research.12003.1>

REVISED Amendments from Version 2

In response to the referees, some spelling mistakes in chemical compounds were modified throughout the paper.

See referee reports

Introduction

Infectious diseases are the main reason for morbidity and mortality in developing countries, especially among children¹. *Staphylococcus aureus* is a common inhabitant of the upper respiratory tract in children, and the causative agent for many infections. It is believed that people under 20 are more likely to have these bacteria. There is a greater possibility that *S. aureus* exists in the respiratory tract of infants aged 3 months or younger than in people of other ages². Moreover, *S. aureus* is colonized in the nasopharynx in 10–35% of children, and in almost 35% of the adult population³.

Escherichia coli is one of the most significant pathogens affecting preterm infants⁴. Some studies in developing countries have suggested that gram-negative rods (such as *E. coli*) are the major causes of infection in premature infants (0–6 days)^{5–7}. Furthermore, infections caused by *E. coli* are one of the most important causes of death in the early neonatal period⁵. *Candida albicans* is an opportunistic pathogen and an agent of nosocomial infection⁸.

Generally, the causative agents of respiratory tract infections are diagnosed in late phases of the disease⁷. Such infections need broad-spectrum antibiotic therapy, the consequences of which are a reduction in the pathogen load, but not eradication. Moreover, such therapies increase the probability of drug-resistant infections spreading⁹. Accurate and rapid detection of pathogens is a critical step for adequate treatment of infection¹⁰, and a non-invasive diagnostic method that has a high degree of accuracy needs to be developed¹¹.

It has been shown that bacteria produce organic gases. Different types of microorganisms have a distinct metabolism, and they produce various types of volatile organic compounds (VOCs)^{12–14}. Attempts have been made to identify the VOCs of pathogenic organisms^{15–20}. There are several sophisticated methods available that have been used for recognizing VOCs; these include gas chromatography-mass spectrometry (GC-MS)²¹, selected ion flow tube mass spectrometry (SIFT-MS)²², electronic noses (eNoses)²³, and ion-molecule reaction mass spectrometry (IMRMS)²⁴. Previous studies suggest that GC-MS is the most appropriate and reliable technique for the isolation and identification of VOCs^{25–27}.

The current study aimed to identify the volatile organic compounds (VOCs) produced by three respiratory tract pathogens, including

Staphylococcus aureus, *Escherichia coli* and *Candida albicans*, to determine if these could be used as biomarkers.

Materials and methods

Model organisms, medium and growth conditions

The bacterial strains used in this study were *E. coli* (ATCC 25922) and *S. aureus* (ATCC 25923), as gram-negative and gram-positive model organisms, and *C. albicans* (ATCC 10231) was used as a human pathogenic fungi model. These organisms were obtained from the Microbiology Laboratory of Medicinal plants and Drugs Research Institute, Shahid Beheshti University. Monocultures of all strains were cultured 24 hours in nutrient agar, and then sub-cultured aerobically at 37°C in 30 ml of two different types of broth medium, Mueller Hinton broth (MB) and tryptic soy broth (TSB), in 100 ml sterilized glass bottles. For a more careful assessment of VOCs produced by each microorganism, the headspace was extracted from both media at three different time points: 2, 4 and 24 hours. To increase the possibility of VOC production, bottles containing cultured microorganism were shaken at 150 rpm during incubation time²⁸. A suspension of microorganisms with approximately OD₆₀₀ ~0.5 in culture media was used during the headspace extraction¹⁰, and the corresponding sterile broth mediums were used as the blank samples²⁹.

Headspace extraction

A solid phase microextraction (SPME) fiber holder (57330-U, Sigma-Aldrich) containing fiber coated with divinyl benzene/carboxen/poly dimethyl siloxane 50/30 µm (DVB/CAR/PDMS) (57328-U, Sigma-Aldrich) was used for absorption of volatile compounds from the headspace of pathogens. To provide conditions that increase the rate of VOC absorption, after incubation time, 2ml of NaCl 36% was added to each culture. Then the DVB/CAR/PDMS fiber was suspended from the top of the bottle containing the culture and placed on a magnetic stirrer hotplate at 70°C for 30 minutes³⁰. After that, the fiber was placed at the injection site of GC-MS and all the absorbed VOCs entered the device. Eventually each VOC is represented as a chromatogram peak in the monitor that is connected to the GC-MS. For thermal desorption, the SPME fiber remained in the injector for 2 minutes before it was exposed to the headspace of the pathogen samples³¹. To avoid possible false discoveries each state was tested at least three times.

GC-MS

To study the bacterial VOCs, a Thermo-Finnigan Trace GC-MS system (Thermo Quest-Finnigan Co) equipped with a DB-5 column (60 m length, 0.25 mm inner diameter, and 0.25 µm film thickness) with helium carrier gas at a flow rate of 1.1 ml/min was used. The starting temperature was 50°C, increasing at a rate of 10°C/minute up to 250°C. The GC-MS was set in splitless mode and a quadrupole ion trap with ionization energy of 70 eV was used in the filament.

VOCs were identified using the [National Institute of Standards and Technology \(NIST\) reference library](#). To analyze the GC-MS

data, Xcalibur 3.0 with Foundation 3.0 SP2 software (Thermo Fisher Scientific) was used, and the Kovats retention index (RI) was calculated for each chromatographic peak.

When calculating the RI, a series of standards were used: n-alkanes were injected into the GC-MS the day before starting experiments, using the same temperature profile that would be used for the analysis of VOCs. The NIST17 Mass Spectral Library (NIST7/2017/EPA/NIH) was used to identify each compound according to its RI. Since there may be several types of volatile compounds have similar RI, to validate the final results extensive studies were also performed by a phytochemist to determine if the compounds were organic. The common VOCs

released from the sterile environment (Blank samples) and tests were not considered.

Results

The VOCs produced by *S. aureus*, *E. coli* and *C. albicans* were assessed under six different conditions (using two types of media and taking measurements at three time points). The Xcalibur raw files for these three pathogens are available at <https://doi.org/10.6084/m9.figshare.5178004.v1>³².

One chromatogram of the six chromatograms obtained is displayed in **Figure 1**, showing the chromatogram obtained 4 hours after culture in TSB medium, for each pathogen. The five

Figure 1. Three chromatograms, for samples taken 4 hours after culture in TSB media. EC: *E. coli*, SA: *S. aureus* and CA: *C. albicans*. The other chromatograms are available in the [Supplementary material](#).

other chromatograms are also available, as [Supplementary File S1](#), [Supplementary File S2](#), [Supplementary File S3](#), [Supplementary File S4](#) and [Supplementary File S5](#).

The processed GC-MS data obtained in the current study is available in a total of 18 tables as supplementary GC-MS data. It shows the details of the VOCs detected for each of the three

pathogens, each analyzed under different conditions (using two types of media and taking measurements at three time points, as explained above).

For a better overview the detected VOCs are shown in three tables (at the 2 hour time point in [Table 1](#), at the 4 hour time point in [Table 2](#) and at the 24 hour time point in [Table 3](#)), alongside the

Table 1. The identified VOCs for *E. coli*, *S. aureus* and *C. albicans*, and the percentage of the total area that their average peak covered (peak area %), after 2 hours in MB and TSB media. In total, 25 types of VOCs by *E. coli*, 33 types by *S. aureus* and 28 types by *C. albicans* were generated in this period.

Compound	<i>E. coli</i> in MB	<i>E. coli</i> in TSB	<i>S. aureus</i> in MB	<i>S. aureus</i> in TSB	<i>C. albicans</i> in MB	<i>C. albicans</i> in TSB
(e)-2-hexyl ester- butanoic acid	1.84	0.79	-	-	6.75	3.78
1-(1,5-dimethyl-4-hexyl-4-methyl-benzene	3.19	0.41	-	-	-	-
1,2-benzenedicarboxylic acid	-	-	0.39	-	-	0.2
1,2-butadiene	-	-	-	1.73	-	-
1,3-butadiene	-	-	-	-	-	26.68
1,3-heptadiene	-	-	-	4.88	-	4.55
1,5-decadiene	-	-	-	-	-	0.86
1,9-decadiene	0.05	0.05	-	-	-	0.39
1-decyne	-	0.07	0.85	-	1.55	1.55
1-penten-3-ol	-	0.02	-	5.14	-	-
2,3-pentandione	-	1.33	-	-	-	-
2,5-(1,1-dimethylethyl)-phenol	0.13	0.1	-	0.11	-	0.43
2,5-dimethyl pyrazine	-	-	-	20.19	-	3.07
2,6-bis(1,1-dimethylethyl)-4-methyl-phenol	-	0.04	0.5	-	-	0.64
2,6-dibutyl-2,5-cyclohexadiene-1,4-dione	0.03	-	-	-	-	-
2-ethenyl-6-methyl-pyrazine	1.1	0.63	6.58	6.63	-	3.63
2-ethyl hexanol	-	-	-	2.32	-	-
2-heptanone	0.05	-	-	2.31	-	-
2-hexan-1-ol	-	-	-	-	-	0.22
2-methyl-2-undecanethiol	0.24	0.13	1.98	1.09	-	-
3-methyl-1,5-heptadiene	-	-	-	-	3.77	1.03
3-propionyloxy pentadecane	0.57	0.18	7.36	1.3	2	0.61
4-t-butyl-2-(1-methyl-2-nitroethyl)cyclohexane	0.93	0.73	12.17	5.4	10.98	2.45
5,5-dodecadinyl-1, 12-diol	-	-	0.48	0.5	1.19	6.38
allyl butylhydroquinone	-	-	-	0.31	-	-
anisol	-	0.05	-	1.19	-	-
benzaldehyde	2.13	1.34	3.22	8.98	-	0.64
benzene acetaldehyde	-	-	8.74	7.04	-	-
benzophenone	0.03	-	-	-	-	-
bisabolene	1.21	0.03	-	-	-	-
butyl cyclohexyl acetate	-	-	-	0.4	-	-
butyraldehyde	-	-	-	-	-	0.67

Compound	<i>E. coli</i> in MB	<i>E. coli</i> in TSB	<i>S. aureus</i> in MB	<i>S. aureus</i> in TSB	<i>C. albicans</i> in MB	<i>C. albicans</i> in TSB
cadinene	-	-	-	-	-	1.79
carbamic acid	-	-	-	-	48.49	0.5
caryophyllene	-	-	-	0.09	-	-
cedran-1,8-diol	0.14	0.09	2.63	0.39	-	0.48
cedrol	-	-	0.71	0.23	-	-
copaene	0.01	-	-	-	-	-
cyclohexene, 4-ethenyl-	-	-	29.64	2.18	-	0.47
decanol	-	0.93	-	-	-	-
decene	-	-	-	2.85	-	-
dimethyl octenal	-	-	-	1.39	-	-
dimethyl ethyl cyclohexanol	-	-	-	1.04	-	0.59
dodecane	0.06	-	-	0.96	-	-
dodecanol	-	0.27	-	-	-	-
dodecenol	-	-	-	-	-	0.5
eicosane	-	-	-	-	-	0.12
ethyl butanoate	-	-	-	-	5.31	4.64
heptadecane	-	-	12.35	5.33	-	-
humulen	-	-	0.71	-	-	-
indole	82.61	90.97	-	0.48	-	-
limonene	0.68	-	-	-	-	-
longifolene	-	-	-	-	4.96	0.43
longifolene	-	-	-	0.52	-	-
methone	-	-	-	7.49	-	1.4
muurola-4,5-diene	0.47	-	-	-	-	-
naphthalenol	-	0.84	-	0.21	-	0.44
neryl acetate	0.06	0.03	-	-	-	-
nonadecanone	-	-	0.62	-	-	-
ocimene	-	-	-	-	-	2.24
octacosane	0.41	0.06	1.37	1.22	1.2	1.02
octyl acetate	-	-	-	-	-	0.4
pentadecane	0.03	-	0.86	0.68	-	4.1
phthalic acid, butyl ester	0.19	0.13	0.97	-	-	0.22
phenyl ethyl pyrrole	-	0.06	-	-	-	-
sesquiphellandrene	1.1	-	-	-	-	4.79
tetra butyl cyclohexyl acetate	-	-	1.7	-	-	-
tetradecane	0.01	-	-	-	-	-
tetradecanol	-	-	-	-	-	0.34
zingiberene	1.63	-	1.03	-	2.87	7.91
α -acetoxidyhydrocoumarin	-	0.52	1.88	0.25	-	-
β -santalol	-	-	-	-	4.87	1.34

Table 2. The identified VOCs for *E. coli*, *S. aureus* and *C. albicans*, and the percentage of the total area that their average peak covered (peak area %), after 4 hours in MB and TSB media. In total, 9 types of VOCs by *E. coli*, 19 types by *S. aureus* and 42 types by *C. albicans* were generated in this period.

Compound	<i>E. coli</i> in MB	<i>E. coli</i> in TSB	<i>S. aureus</i> in MB	<i>S. aureus</i> in TSB	<i>C. albicans</i> in MB	<i>C. albicans</i> in TSB
(e)-2-hexyl ester-butanoic acid	-	-	-	-	6.64	4.24
(z)-2-octene-1-ol	-	-	-	-	0.69	0.54
(z)-4-decan-1-ol	-	-	-	-	0.70	0.46
1,2-benzenedicarboxylic acid	-	-	-	-	0.29	0.31
1,2-butadiene	-	-	0.37	4.02	-	-
1,3-butadiene	-	-	-	-	1.40	-
1,3-heptadiene	-	-	81.33	-	0.23	0.47
1,5-decadiene	-	-	-	-	1.01	3.00
1,9-decadiene	-	0.01	-	-	0.20	3.59
1-decyne	2.36	-	0.59	16.47	2.81	1.40
1-methoxy-2-propanol	-	-	0.20	-	-	-
2-(phenylmethylene)-octanal	-	-	-	-	1.55	1.63
2,3-pentandione	-	-	7.07	21.67	-	-
2,5-(1,1-dimethylethyl)-phenol	-	-	-	-	0.69	0.43
2,5-dimethyl pyrazine	-	-	-	-	-	3.48
2-acetyl-1-pyrroline	-	0.07	-	-	-	-
2-ethenyl-6-methyl-pyrazine	0.01	-	0.80	-	7.33	-
2-ethyl hexanol	-	-	-	1.05	-	-
2-heptanone	0.02	0.33	-	-	-	-
2-hexan-1-ol	-	-	-	-	0.33	0.23
2h-tetrazole-5-carboxylic acid, 2-phenyl	-	-	0.48	-	1.44	1.59
2-methyl-2-undecanethiol	-	-	0.24	-	-	-
3-methyl-1,5-heptadiene	-	-	0.60	-	0.76	0.53
4-t-butyl-2-(1-methyl-2-nitroethyl)cyclohexane	-	-	-	-	6.05	5.81
5,5-dodecadynyl-1, 12-diol	-	-	-	-	5.16	0.51
6-methyl-5-hepten-2-one	-	-	-	-	0.31	0.20
benzaldehyde	-	-	-	-	0.83	0.68
butyraldehyde	-	-	0.38	-	-	-
cadinene	-	-	-	-	0.79	0.34
carbamic acid	-	-	-	-	18.10	8.19
caryophyllene	-	0.02	-	4.88	-	-
cedrol	-	-	-	-	0.36	0.36
cis-dihydro- α -terpinyl acetate	-	-	-	17.90	-	-
cyclohexene, 4-ethenyl-	-	-	0.08	6.77	-	-
dimethyl octenal	-	-	-	-	0.58	-
dimethylethyl cyclohexanol	-	-	-	-	0.79	0.22
dodecenal	-	-	-	-	0.52	0.39
dodecenol	-	-	-	-	0.61	2.54
eicosane	-	-	-	-	-	0.29

Compound	<i>E. coli</i> in MB	<i>E. coli</i> in TSB	<i>S. aureus</i> in MB	<i>S. aureus</i> in TSB	<i>C. albicans</i> in MB	<i>C. albicans</i> in TSB
ethyl butanoate	0.01	-	7.57	12.21	6.63	0.73
indole	97.05	99.46	-	0.82	0.34	-
levomenthol	-	-	-	3.74	-	-
longifolene	-	-	-	-	0.31	0.26
longifolol	-	-	-	-	5.66	22.07
methyl isopropyl hexenal	-	-	-	-	1.11	0.59
naphthalenol	-	-	-	-	-	0.37
octacosane	-	-	-	-	1.74	1.60
octyl acetate	-	-	-	-	0.34	-
pentadecane	-	-	-	0.87	1.80	1.38
phthalic acid, butyl ester	-	-	-	-	0.60	0.36
tetradecanol	-	-	-	-	0.61	0.26
tridecanol	-	-	-	-	0.34	0.34
zingiberene	-	-	-	-	1.27	1.12
β -santalol	-	0.03	-	5.16	6.52	14.15
sesquiphellandrene	-	-	-	-	2.00	0.70

Table 3. The identified VOCs for *E. coli*, *S. aureus* and *C. albicans*, and the percentage of the total area that their average peak covered (peak area %), after 24 hours in MB and TSB media. In total, 16 types of VOCs by *E. coli*, 26 types by *S. aureus* and 27 types by *C. albicans* were generated in this period.

Compound	<i>E. coli</i> in MB	<i>E. coli</i> in TSB	<i>S. aureus</i> in MB	<i>S. aureus</i> in TSB	<i>C. albicans</i> in MB	<i>C. albicans</i> in TSB
(e)-2-hexyl ester-butanoic acid	0.04	0.03	0.21	0.04	0.50	-
(z)-2-octene-1-ol	-	-	-	-	-	0.18
(z)-4-decan-1-ol	-	-	-	-	-	0.60
1,2-benzenedicarboxylic acid	-	-	-	-	0.13	0.28
1,2-butadiene	-	-	3.71	0.10	-	-
1,3-heptadiene	-	-	21.75	-	-	-
1,5-decadiene	-	-	-	-	0.10	0.26
1,9-decadiene	0.02	0.03	-	-	-	-
1-decyne	-	0.02	0.81	59.78	-	0.75
1-methoxy-2-propanol	-	-	6.74	0.02	-	-
2-(phenylmethylene)-octanal	-	-	-	-	0.71	0.86
2,3-pentandione	0.03	0.48	15.53	0.66	-	-
2,5-dimethyl pyrazine	-	-	0.62	-	-	0.55
2-acetyl-1-pyrroline	-	6.37	-	1.11	-	-
2-decenal	-	-	0.06	0.01	-	-
2-ethenyl-6-methyl-pyrazine	0.06	-	1.35	-	0.39	-
2-ethyl hexanol	-	-	0.13	0.02	-	0.51
2-heptanone	-	0.21	-	-	-	-

Compound	<i>E. coli</i> in MB	<i>E. coli</i> in TSB	<i>S. aureus</i> in MB	<i>S. aureus</i> in TSB	<i>C. albicans</i> in MB	<i>C. albicans</i> in TSB
2h-tetrazole-5-carboxylic acid, 2-phenyl	-	-	3.21	-	-	-
2-methyl tetradecane	0.05	0.03	-	-	-	-
2-methyl-1-propanol	-	-	0.15	0.04	5.89	16.03
2-methyl-2-undecanethiol	0.10	-	2.54	-	-	61.65
2-octyl-1-ol	-	-	-	-	0.15	-
2-octyne	-	-	-	-	-	0.27
3-methyl-4-pentene-3-ol	-	-	-	-	-	0.13
3-methyl-1,5-heptadiene	-	-	0.19	-	-	-
3-methyl-1-pentene	-	-	-	-	-	0.41
-4-t-butyl-2-(1-methyl-2-nitroethyl)cyclohexane	-	-	-	-	80.87	-
5.5-dodecadynyl-1, 12-diol	0.01	0.03	0.77	0.05	-	-
butyraldehyde	-	-	1.41	0.09	0.14	0.24
carbamic acid	-	-	-	-	0.48	-
caryophyllene	-	0.21	-	0.14	-	1.25
cedrol	-	-	-	-	1.93	2.68
cis-dihydro- α -terpinyl acetate	-	0.64	-	34.77	-	-
cyclohexene, 4-ethenyl-	-	-	3.54	0.15	-	-
ethyl acetoacetate	-	-	-	-	-	0.46
ethyl butanoate	0.06	0.31	28.72	0.46	-	1.64
indole	99.61	88.86	0.07	0.02	-	-
levomenthol	-	-	-	1.66	-	-
longifolol	-	-	-	-	0.33	0.24
octacosane	-	-	-	-	0.33	0.44
pentadecane	-	0.35	0.17	0.08	-	-
thiophene	-	-	0.18	-	-	-
zingiberene	-	-	-	-	0.20	-
β -santalol	-	0.49	-	0.21	-	1.21

percentage of the total area that the average peak of the detected VOC covered. In other words it is proportional to amount of the compound that is present.

Some VOCs were common among organisms and were generated by two or three organisms at an approximately equal rate, including 1,2-benzenedicarboxylic acid, 1,9-decadiene, 2,5-(1,1-dimethylethyl)-phenol, 2,6-bis(1,1-dimethylethyl)-4-methyl-phenol, 3-propionyl oxy pentadecane and anisol (Table 1). Some common VOCs were produced at a greater rate between one organism and another. It can be concluded that these VOCs could also be more important in the organism that produces greater quantities. 1-penten-3-ol was produced from *E. coli* in TSB medium after

2 hours (0.02%); under identical conditions, more of it was produced by *S. aureus* (5.14%) than by *E. coli*. Furthermore, indole was produced from *E. coli* after 2 hours of culture in two types of medium (82.61% for MB and 90.97% for TSB) and was also produced by *S. aureus* after 2 hours in TSB medium, although at a much lower rate (0.48%) (Table 1).

Uncommon VOCs of *E. coli* detected 2 hours after culture included 1-(1,5-dimethyl)-4-hexyl-4-methyl-benzene, 2,3-pentandione, 2,6-dibutyl-2,5-cyclohexadiene-1,4-dione, benzophenone, bisabolene, copaene, decanol, dodecanol, indole, limonene, muurola-4,5-diene, neryl acetate, phenyl ethyl pyrrole and tetradecane (Table 1).

Uncommon VOCs of *S. aureus* detected 2 hours after culture included 1,2-butadiene, 1-penten-3-ol, 2,5-dimethyl pyrazine, 2-ethyl hexanol, allyl butyl hydroquinone, benzene acetaldehyde, butyl cyclohexyl acetate, caryophyllene, cedrol, cyclohexene, 4-ethenyl-, decene, dimethyl octenal, heptadecane, humulen, longifolene, methone, nonadecanone and tetrabutyl cyclohexyl acetate (Table 1).

Uncommon VOCs of *C. albicans* detected 2 hours after culture included 1,3-butadiene, 1,5-decadiene, 2-hexan-1-ol, 3-methyl-1, 5-heptadiene, butyraldehyde, cadinene, carbamic acid, dodecanol, eicosane, ethyl butanoate, longifolene, ocimene, octyl acetate, tetradecanol and β -santalolol (Table 1).

Uncommon VOCs of *E. coli* identified 4 hours after culture included 1,9-decadiene, 2-acetyl-1-pyrroline, 2-heptanone and indole (Table 2).

Uncommon VOCs of *S. aureus* identified 4 hours after culture included 1,2-butadiene, 1,3-heptadiene, 1-decyne, 1-methoxy-2-propanol, 2,3-pentandione, 2-ethyl hexanol, 2-methyl-2-undecanethiol, butyraldehyde, cis-dihydro- α -terpinyl acetate, cyclohexene, 4-ethenyl- and levomenthol (Table 2).

Uncommon VOCs of *C. albicans* identified 4 hours after culture included (e)-2-hexyl ester- butanoic acid, (z)-2-octene-1-ol, (z)-4-decan-1-ol, 1,2-benzenedicarboxylic acid, 1,3-butadiene, 1,5-decadiene, 2-(phenyl methylene)-octanal, 2,5-(1,1-dimethylethyl)-phenol, 2,5-dimethyl pyrazine, 2-ethenyl-6-methyl-pyrazine, 2-hexan-1-ol, 4-t-butyl-2-(1-methyl-2-nitroethyl) cyclohexane, 5,5-dodecadynyl-1, 12-diol, 6-methyl-5-hepten-2-one, benzaldehyde, cadinene, carbamic acid, cedrol, dimethyl octenal, dimethyl ethyl cyclohexanol, dodecanol, dodecenol, eicosane, longifolene, longifolol, methyl isopropyl hexenal, naphthalenol, octacosane, octyl acetate, phthalic acid butyl ester, tetradecanol, tridecanol, zingiberene and sesquiphellandrene (Table 2).

Uncommon VOCs of *E. coli* identified 24 hours after culture included 1,9-decadiene, 2-acetyl-1-pyrroline, 2-heptanone, 2-methyl tetradecane and indole (Table 3).

Uncommon VOCs of *S. aureus* identified in 24 hours after culture were included; 1,2-butadiene, 1,3-heptadiene, 1-decyne, 1-methoxy-2-propanol, 2,3-pentandione, 2,5-dimethyl pyrazine, 2-decenal, 2h-tetrazole-5-carboxylic acid, 2-phenyl, 3-methyl-1, 5-heptadiene, caryophyllene, cis-dihydro- α -terpinyl acetate, cyclohexene, 4-ethenyl-, ethyl butanoate, levomenthol and thiophene (Table 3).

Uncommon VOCs of *C. albicans* identified 24 hours after culture included (z)-2-octene-1-ol, (z)-4-decan-1-ol, 1,2-benzenedicarboxylic acid, 1,5-decadiene, 2-(phenyl methylene)-octanal, 2,5-dimethyl pyrazine, 2-methyl-1-propanol, 2-methyl-2-undecanethiol, 2-octyl-1-ol, 2-octyne, 3-methyl-4-pentene-3-ol, 3-methyl-1-pentene, 4-t-butyl-2-(1-methyl-2-nitroethyl) cyclohexane, carbamic acid, cedrol, ethyl acetoacetate, longifolol, octacosane and zingiberene (Table 3).

Discussion

As previous studies have shown, organisms are able to produce either common or specific VOCs³³⁻³⁵. In the current study, GC-MS was used to detect VOCs generated by three pathogenic organisms in the human respiratory tract. The VOCs of *E. coli*, *S. aureus* and *C. albicans* were analyzed at three different time points, using two different types of media (Figure 1).

Results of the current study suggest that VOCs exclusively produced by *E. coli* are 1-(1,5-dimethyl)-4-hexyl-4-methyl-benzene, 2,6-dibutyl-2,5-cyclohexadiene-1,4-dione, benzophenone, bisabolene, copaene, decanol, dodecanol, indole, limonene, muurola-4,5-diene, nerylacetate, phenyl ethyl pyrrole, sesquiphellandrene, tetradecane, 2-acetyl-1-pyrroline and 2-methyl tetradecane. The most important compound among these is Indole, because it is generated at the three time points and also it was the most produced VOC by *E. coli* (at least 82%). Other studies have confirmed this finding^{28,29,35}. *E. coli* produced tryptophanase and this enzyme degrades tryptophan to indole and the other compounds³⁶. In future studies, it is advisable to measure the amount of indole in the exhaled air of infected patients with *E. coli* and compare it with the current results. This is because in the patient's lungs the level of tryptophan is not the same as culture medium. It is also suggested that the amount of released indole from this bacterium should be evaluated under *in-vitro* conditions and with using the simplest culture medium (relative to TSB and MB). In this way, we will have a more detailed thought of the importance of the Indole production by *E. coli*.

The current study has shown that the specific VOCs produced by *S. aureus* are 1,2-butadiene, 1-penten-3-ol, 2,5-dimethyl pyrazine, 2-ethyl hexanol, allyl butyl hydroquinone, benzene acetaldehyde, butylcyclohexyl acetate, caryophyllene, cyclohexene, 4-ethenyl-, decene, heptadecane, humulen, longifolene, methone, nonadecanone, tetrabutylcyclohexyl acetate, 1,3-heptadiene, 1-decyne, 1-methoxy-2-propanol, 2,3-pentandione, cis-dihydro- α -terpinyl acetate, levomenthol, 2-decenal, ethyl butanoate and thiophene. Moreover, 1,2-butadiene, 2,5-dimethyl pyrazine, 2-ethyl hexanol, caryophyllene, cyclohexene, 4-ethenyl, 1,3-heptadiene, 1-decyne, 1-methoxy-2-propanol, 2,3-pentandione, cis-dihydro- α -terpinyl acetate, and levomenthol were detected under more than one of the six conditions that were tested, so they are significant. Another important point is that the percentage of the total area that the average peaks for 2,3-pentandione, cis-dihydro- α -terpinyl acetate, 1-decyne, 1,3-heptadiene, 2,5-dimethyl pyrazine, ethyl butanoate and cyclohexene, 4-ethenyl covered were at least 15%; thus, they are remarkable VOCs for *S. aureus*. Some of the VOCs produced by *S. aureus* in the current study have been reported in other studies^{34,37} but some of them have not^{28,33}. The origin of all produced VOCs is not exactly known. However it is believed some released VOCs by this bacterium is because of the ability to degrade amino acids in its growth environment¹¹.

This study suggested that the specific VOCs produced by *C. albicans* include 1,3-butadiene, 1,5-decadiene, 2-hexan-1-ol, cadinene, carbamic acid, dodecanol, eicosane, longifolene, ocimene, octyl acetate, tetradecanol, β -sesquiphellandrene,

(z)-2-octene-1-ol, (z)-4-decan-1-ol, 2-(phenyl methylene)-octanal, 4-t-butyl-2-(1-methyl-2-nitroethyl) cyclohexane, longifolol, 6-methyl-5-hepten-2-one, dodecenal, methyl isopropyl hexenal, tridecanol, 2-methyl-2-undecanethiol, 2-octyl-1-ol, 2-octyne, 3-methyl-4-pentene-3-ol, 2-methyl-1-propanol and 3-methyl-1-pentene. also, 1,3-butadiene, 1,5-decadiene, 2-hexan-1-ol, cadinene, carbamic acid, dodecanol, eicosane, longifolene, octyl acetate, tetradecanol, β -sesquiphellandrene, (z)-2-octene-1-ol, (z)-4-decan-1-ol, 2-(phenyl methylene)-octanal, 4-t-butyl-2-(1-methyl-2-nitroethyl) cyclohexane, longifolol, octyl acetate, β -sesquiphellandrene and 2-methyl-2-undecanethiol were detected under more than one of the six conditions that were tested, so they are significant. Furthermore, 1,3-butadiene, carbamic acid, longifolol, β -santalol, 2-methyl-1-propanol, 2-methyl-2-undecanethiol and 4-t-butyl-2-(1-methyl-2-nitroethyl) cyclohexane were produced in greater quantities. Several studies have analyzed the VOCs of *C. albicans* and have noted that most of these identified compounds are alcohols^{38–40}. That is because if favorable growth conditions are available for this bacterium (a sufficient level of oxygen, aromatic amino acids, and an alkaline pH) will produce large amounts of alcohol that results from its metabolism⁴¹.

It is suggested that the findings of future studies on the exhaust air of respiratory infections patients with these three pathogens should be compared with the identified VOCs in this study. Although there may be some differences between the results of *in-vitro* and *in-vivo* studies there seems to be significant similarities over the dominant detected VOCs.

Finding a non-invasive and rapid method for diagnosis of infectious agents is a subject of interest, so it has been investigated in several studies^{33,42–45}. The current study showed that using SPME

fiber and GC-MS for extraction and detection of VOCs allowed detection of more specific VOCs for the three pathogenic respiratory tract organisms, *E. coli*, *S. aureus* and *C. albicans*, which could be used as biomarkers for their identification. It is essential that more comprehensive studies be conducted to create a more complete profile of VOCs for these organisms, and so that the methods can be developed further.

Data availability

The Xcalibur raw files for the three studied pathogens are available at <https://doi.org/10.6084/m9.figshare.5178004.v1>³².

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by the Shahid Beheshti University of Medical Sciences.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

This paper is part of Najmeh Karami's PhD thesis, named: "Identification the volatile metabolic profiling of six respiratory pathogenic organisms". We would like to express our specific thanks to Shahid Beheshti University of Medical Sciences for the financial support. We also appreciate all colleagues that helped us in the Pediatric Infections Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences and Medicinal Plant and Drug Research Institute, Shahid Beheshti.

Supplementary material

Supplementary File S1: Three chromatograms, for samples taken 2 hours after culture in MB media. EC: *E. coli*, SA: *S. aureus* and CA: *C. albicans*.

[Click here to access the data.](#)

Supplementary File S2: Three chromatograms, for samples taken 4 hours after culture in MB media. EC: *E. coli*, SA: *S. aureus* and CA: *C. albicans*.

[Click here to access the data.](#)

Supplementary File S3: Three chromatograms, for samples taken 24 hours after culture in MB media. EC: *E. coli*, SA: *S. aureus* and CA: *C. albicans*.

[Click here to access the data.](#)

Supplementary File S4: Three chromatograms, for samples taken 2 hours after culture in TSB media. EC: *E. coli*, SA: *S. aureus* and CA: *C. albicans*.

[Click here to access the data.](#)

Supplementary File S5: Three chromatograms, for samples taken 24 hours after culture in TSB media. EC: *E. coli*, SA: *S. aureus* and CA: *C. albicans*.

[Click here to access the data.](#)

Supplementary File S6: GC-MS data analysis, showing the details of the detected VOCs of three pathogens in 6 modes.

[Click here to access the data.](#)

References

1. Rodríguez L, Cervantes E, Ortiz R: **Malnutrition and gastrointestinal and respiratory infections in children: a public health problem.** *Int J Environ Res Public Health*. 2011; **8**(4): 1174–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Huang YC, Chen CJ: **Nasal carriage of methicillin-resistant *Staphylococcus aureus* during the first 2 years of life in children in northern Taiwan.** *Pediatr Infect Dis J*. 2015; **34**(2): 131–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Regev-Yochay G, Dagan R, Raz M, *et al.*: **Association between carriage of *Streptococcus pneumoniae* and *Staphylococcus aureus* in children.** *JAMA*. 2004; **292**(6): 716–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Stoll BJ, Hansen NI, Sánchez PJ, *et al.*: **Early onset neonatal sepsis: the burden of group B *Streptococcus* and *E. coli* disease continues.** *Pediatrics*. 2011; **127**(5): 817–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Walker CL, Rudan I, Liu L, *et al.*: **Global burden of childhood pneumonia and diarrhoea.** *Lancet*. 2013; **381**(9875): 1405–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Russo TA, Johnson JR: **Medical and economic impact of extraintestinal infections due to *Escherichia coli*: focus on an increasingly important endemic problem.** *Microbes Infect*. 2003; **5**(5): 449–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Zaidi AK, Huskins WC, Thaver D, *et al.*: **Hospital-acquired neonatal infections in developing countries.** *Lancet*. 2005; **365**(9465): 1175–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Pierce GE: ***Pseudomonas aeruginosa*, *Candida albicans*, and device-related nosocomial infections: implications, trends, and potential approaches for control.** *J Ind Microbiol Biotechnol*. 2005; **32**(7): 309–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Filipiak W, Sponring A, Baur MM, *et al.*: **Characterization of volatile metabolites taken up by or released from *Streptococcus pneumoniae* and *Haemophilus influenzae* by using GC-MS.** *Microbiology*. 2012; **158**(Pt 12): 3044–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Pauwels RA, Buist AS, Calverley PM, *et al.*: **Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.** *American journal of respiratory and critical care medicine*. 2012.
11. Filipiak W, Sponring A, Baur MM, *et al.*: **Molecular analysis of volatile metabolites released specifically by *Staphylococcus aureus* and *Pseudomonas aeruginosa*.** *BMC Microbiol*. 2012; **12**(1): 113.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Schulz S, Dickschat JS: **Bacterial volatiles: the smell of small organisms.** *Nat Prod Rep*. 2007; **24**(4): 814–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Thorn RM, Reynolds DM, Greenman J: **Multivariate analysis of bacterial volatile compound profiles for discrimination between selected species and strains *in vitro*.** *J Microbiol Methods*. 2011; **84**(2): 258–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Wilson AD, Baietto M: **Advances in electronic-nose technologies developed for biomedical applications.** *Sensors (Basel)*. 2011; **11**(1): 1105–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Barker M, Hengst M, Schmid J, *et al.*: **Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis.** *Eur Respir J*. 2006; **27**(5): 929–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Buszewski B, Keszy M, Ligor T, *et al.*: **Human exhaled air analytics: biomarkers of diseases.** *Biomed Chromatogr*. 2007; **21**(6): 553–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Hamilton-Kemp T, Newman M, Collins R, *et al.*: **Production of the long-chain alcohols octanol, decanol, and dodecanol by *Escherichia coli*.** *Curr Microbiol*. 2005; **51**(2): 82–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Julák J, Stránská E, Procházková-Francisci E, *et al.*: **Blood cultures evaluation by gas chromatography of volatile fatty acids.** *Med Sci Monit*. 2000; **6**(3): 605–10.
[PubMed Abstract](#)
19. Friedrich MJ: **Scientists seek to sniff out diseases: electronic “noses” may someday be diagnostic tools.** *JAMA*. 2009; **301**(6): 585–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Röck F, Barsan N, Weimar U: **Electronic nose: current status and future trends.** *Chem Rev*. 2008; **108**(2): 705–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Farag MA, Ryu CM, Sumner LW, *et al.*: **GC–MS SPME profiling of rhizobacterial volatiles reveals prospective inducers of growth promotion and induced systemic resistance in plants.** *Phytochemistry*. 2006; **67**(20): 2262–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Allardyce RA, Langford VS, Hill AL, *et al.*: **Detection of volatile metabolites produced by bacterial growth in blood culture media by selected ion flow tube mass spectrometry (SIFT-MS).** *J Microbiol Methods*. 2006; **65**(2): 361–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. de Heer K, van der Schee MP, Zwinderman K, *et al.*: **Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study.** *J Clin Microbiol*. 2013; **51**(5): 1490–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Dolch ME, Frey L, Hornuss C, *et al.*: **Molecular breath-gas analysis by online mass spectrometry in mechanically ventilated patients: a new software-based method of CO₂-controlled alveolar gas monitoring.** *J Breath Res*. 2008; **2**(3): 037010.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Bos LD, Sterk PJ, Schultz MJ: **Volatile metabolites of pathogens: a systematic review.** *PLoS Pathog*. 2013; **9**(5): e1003311.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Reade S, Mayor A, Aggio R, *et al.*: **Optimisation of sample preparation for direct SPME-GC-MS analysis of murine and human faecal volatile organic compounds for metabolomic studies.** *J Anal Bioanal Tech*. 2014; **5**(2): 184.
[Publisher Full Text](#)
27. Karami N, Karimi A, Aliahmadi A, *et al.*: **Identification of bacteria using volatile organic compounds.** *Cell Mol Biol (Noisy-le-grand)*. 2017; **63**(2): 112–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Zhu J, Bean HD, Kuo YM, *et al.*: **Fast detection of volatile organic compounds from bacterial cultures by secondary electrospray ionization-mass spectrometry.** *J Clin Microbiol*. 2010; **48**(12): 4426–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Tait E, Perry JD, Stanforth SP, *et al.*: **Identification of volatile organic compounds produced by bacteria using HS-SPME-GC-MS.** *J Chromatogr Sci*. 2014; **52**(4): 363–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Schulz S, Fuhendorff J, Reichenbach H: **Identification and synthesis of volatiles released by the myxobacterium *Chondromyces crocatus*.** *Tetrahedron*. 2004; **60**(17): 3863–72.
[Publisher Full Text](#)
31. Tait E, Hill KA, Perry JD, *et al.*: **Development of a novel method for detection of *Clostridium difficile* using HS-SPME-GC-MS.** *J Appl Microbiol*. 2014; **116**(4): 1010–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Karami N, Mirzajani F, Rezadoost H, *et al.*: **Diagnosis of Three Different Pathogenic Microorganisms by Gas chromatography–mass spectrometry.** *figshare*.
[Data Source](#)
33. Boots AW, Smolinska A, van Berkel JJ, *et al.*: **Identification of microorganisms based on headspace analysis of volatile organic compounds by gas chromatography-mass spectrometry.** *J Breath Res*. 2014; **8**(2): 027106.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Effmert U, Kalderás J, Warnke R, *et al.*: **Volatile mediated interactions between bacteria and fungi in the soil.** *J Chem Ecol*. 2012; **38**(6): 665–703.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Garner CE, Smith S, de Lacy Costello B, *et al.*: **Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease.** *FASEB J*. 2007; **21**(8): 1675–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Martino PD, Fursy R, Bret L, *et al.*: **Indole can act as an extracellular signal to regulate biofilm formation of *Escherichia coli* and other indole-producing bacteria.** *Can J Microbiol*. 2003; **49**(7): 443–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Nizio KD, Perrault KA, Troobnikoff AN, *et al.*: ***In vitro* volatile organic compound profiling using GC×GC-TOFMS to differentiate bacteria associated with lung infections: a proof-of-concept study.** *J Breath Res*. 2016; **10**(2): 026008.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Hertel M, Hartwig S, Schütte E, *et al.*: **Identification of signature volatiles to discriminate *Candida albicans*, *glabrata*, *krusei* and *tropicalis* using gas chromatography and mass spectrometry.** *Mycoses*. 2016; **59**(2): 117–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Perl T, Jünger M, Vautz W, *et al.*: **Detection of characteristic metabolites of *Aspergillus fumigatus* and *Candida* species using ion mobility spectrometry-metabolic profiling by volatile organic compounds.** *Mycoses*. 2011; **54**(6): e828–e37.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Zehm S, Schweinitz S, Würzner R, *et al.*: **Detection of *Candida albicans* by mass spectrometric fingerprinting.** *Curr Microbiol*. 2012; **64**(3): 271–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Ghosh S, Kebaara BW, Atkin AL, *et al.*: **Regulation of aromatic alcohol production in *Candida albicans*.** *Appl Environ Microbiol*. 2008; **74**(23): 7211–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Basanta M, Jarvis RM, Xu Y, *et al.*: **Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers.** *Analyst*. 2010; **135**(2): 315–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Bean HD, Dimandja JM, Hill JE: **Bacterial volatile discovery using solid phase microextraction and comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry.** *J Chromatogr B Anal Technol Biomed Life Sci*. 2012; **901**: 41–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Bean HD, Zhu J, Hill JE: **Characterizing bacterial volatiles using secondary electrospray ionization mass spectrometry (SESI-MS).** *J Vis Exp*. 2011; **(52)**: pii: 2664.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Bunge M, Araghpour N, Mikoviny T, *et al.*: **On-line monitoring of microbial volatile metabolites by proton transfer reaction-mass spectrometry.** *Appl Environ Microbiol*. 2008; **74**(7): 2179–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 3

Reviewer Report 31 January 2018

<https://doi.org/10.5256/f1000research.14954.r29971>

© 2018 Scott-Thomas A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amy Scott-Thomas

University of Otago, University of Otago, New Zealand

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2

Reviewer Report 10 January 2018

<https://doi.org/10.5256/f1000research.14519.r28936>

© 2018 Brinkman P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paul Brinkman

Department of Respiratory Medicine, Academic Medical Center, Amsterdam, The Netherlands

I would like to thank the authors for their response. Although most questions are answered, one question remains open to me:

- Considering they have performed their tests in triplicate, which statistical test did the authors use to compare outcomes between and within blank and actual samples?

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 08 January 2018

<https://doi.org/10.5256/f1000research.14519.r28937>

© 2018 Ratcliffe N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Norman Ratcliffe

Institute of Biosensor Technology, University of the West of England, Bristol, UK

The paper shows some interesting preliminary results. The authors should be complimented for their good English. The works cries out for more repeats and the authors appreciate this. Within the abstract, and in the text throughout, chemical names should not have capital letters, more importantly some of the compound names need checking, particularly 1,3-heptadiene-3-yne which is in the abstract, it cannot be right.

Also check in tables, spelling and also are you sure:

1,2-Benzene dicarboxylic acid, this should be 1,2-benzenedicarboxylic acid

1,3-Butadiene, do you mean 1,3-butadiene?

Likewise 1,2-Butadiene ?

1,3-Heptadiene-3-yne? Can't be

Dibutyl phthalate should be phthalate, also its other name is **1,2-Benzenedicarboxylic acid, dibutyl ester**. Best to be consistent with names, I only draw attention to this case as an example, because 1,2-benzene dicarboxylic acid has been stated to be found, and when they have the same naming, it brings out the thought that the acid may have come from the ester (I say this, rather than the other way around as the butyl ester is a common plasticizer, and can be a contaminant). Longifolr spelling! And it appears just below, they are the same? Do they have the same rts?

Longifolene

Phthalic acid, butyl ester, spelling

Sesquiphellandrene and beta- Sesquiphellandrene, are both listed are they the same?

Table 2,3

Check as above.

There are some compounds, which may be speculatively assigned, eg 4-t-butyl-2-(1-methyl-2-nitroethyl)cyclohexane? Are the authors really sure

Supplementary : E. coli:5.5-Dodecadinyl-1, 12-diol, can't be right, check, plus check names of chemicals as above

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 27 November 2017

<https://doi.org/10.5256/f1000research.12982.r27814>

© 2017 Ratcliffe N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Norman Ratcliffe

Institute of Biosensor Technology, University of the West of England, Bristol, UK

The researchers tackle an area of significant interest, rapid determination of bacterial species, especially associated with life threatening illness, using a relatively new approach, that of VOC analyses. In general the paper reads well.

The analytical method for VOC analyses is ok. Could the authors confirm whether the cfu/ml count is approx. for the different species at the same time points to enable a good comparison of VOCs to be made. One major weakness to the work is that only one analysis for each species at one time point and media was undertaken, the literature gives examples of several analyses being undertaken for similar studies. The title is too ambitious, rather than diagnoses being purported, maybe an "initial study of..." would be more accurate.

The authors could comment on how their research would ultimately fit into a clinical test, if the VOCs were to be analysed in breath, would the same volatile profile be expected?

In the text it was stated that "Extensive studies were also performed by a phytochemist to determine if the compounds were organic", some explanation would be good as to what this means.

Some other matters, VOC abbreviation used twice in the abstract, also in quite a few places the chemical names have capital letters and are misspelt and merged with another word.

In Results, what is uncommon determined by, some more discussion on stats...

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

No

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 15 November 2017

<https://doi.org/10.5256/f1000research.12982.r25909>

© 2017 Scott-Thomas A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amy Scott-Thomas

University of Otago, University of Otago, New Zealand

This paper looks at the detection of VOC's produced by *Escherichia coli*, *Staphylococcus aureus* and *Candida albicans* using solid phase micro-extraction coupled with gas chromatography / mass spectrometry.

It seems as though the group only ran this experiment once so while they have pointed out the detection of specific volatiles at differing time points this needs to be repeated to ensure that it is indeed a true and repeatable release from the micro-organisms.

The work is outlined clearly and the results listed comprehensively however there has been no in-depth discussion surrounding why these volatiles have been produced in vitro, would they be produced in vivo nor an extensive list of references to back this up.

While they state Indole as the most important volatile produced by *E. coli* they do not go into any detail regarding how this would relate to an actual breath test since indole can be released by mouth flora. Also as indole is produced from tryptophan discussion around the levels of tryptophan in the lung and therefore its actual availability to *E. coli* growing in the lung is pertinent. Growth in a minimal media with varying tryptophan levels would give more insight.

It would have also been beneficial to look at the effect of co-culturing these micro-organisms as this may alter the release of the detected VOC's and initiated the production of others.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 08 September 2017

<https://doi.org/10.5256/f1000research.12982.r25394>

© 2017 Brinkman P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paul Brinkman

Department of Respiratory Medicine, Academic Medical Center, Amsterdam, The Netherlands

General Comments:

This study aimed to identify typical volatile organic compounds (VOCs) produced by *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans* by extraction of cultured bacterial strain headspace using solid phase microextraction (SPME) fibers analyzed by Gas Chromatography-Mass Spectrometry (GC-MS). Although the aim of study is obvious and very relevant data is shown, some extension on utilized statistics is needed. Additionally, a replication and/or validation of findings is crucial. The authors do show that some of the VOCs, e.g. Indole, are revealed at multiple time points, but confirmation of observations by repetition of experiments is recommended.

Major Comments:

- To avoid possible false discoveries a repetition of experiments is recommended.

- Which (statistical) methods were used in order to compare blank vs. actual samples?
- Which criteria were applied in order to confirm a 'match' between detected volatiles and the NIST library?
- The authors nicely show the overlap and/or discrepancy between their findings and current available literature, but what about the interpretation of findings? Can the authors extend and/or speculate about possible biological mechanisms behind the revealed VOCs

Minor comment:

- Please consider as reference: Neerincx *et al*; Identification of *Pseudomonas aeruginosa* and *Aspergillus fumigatus* mono- and co-cultures based on volatile biomarker combinations; J Breath Res. 2016 Jan 29;10(1):016002.

References

1. Neerincx AH, Geurts BP, Habets MF, Booij JA, et al.: Identification of *Pseudomonas aeruginosa* and *Aspergillus fumigatus* mono- and co-cultures based on volatile biomarker combinations./ *Breath Res.* 2016; **10** (1): 016002 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research